New hope for a cure: expanding lifesaving transplants for sickle cell patients
NCT ID NCT06358638
Summary
This study is testing if adding a drug called daratumumab before a bone marrow transplant from a matched sibling can safely cure sickle cell disease. It focuses on patients who have been excluded from this curative treatment because their blood type doesn't perfectly match their donor's, which can cause serious complications. The goal is to see if this approach allows these patients to have the same successful outcomes as those with perfect matches.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.